The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review

HS Rugo, I Jacobs, S Sharma, F Scappaticci… - Advances in …, 2020 - Springer
Epigenetic processes are essential for normal development and the maintenance of tissue-
specific gene expression in mammals. Changes in gene expression and malignant cellular …

Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery

Y Wang, W Hu, Y Yuan - Journal of medicinal chemistry, 2018 - ACS Publications
PRMT5 is a major enzyme responsible for symmetric dimethylation of arginine residues on
both histone and non-histone proteins, regulating many biological pathways in mammalian …

Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body …

N Blagitko-Dorfs, P Schlosser, G Greve, D Pfeifer… - Leukemia, 2019 - nature.com
DNA methyltransferase inhibitors (DNMTi) approved for older AML patients are clinically
tested in combination with histone deacetylase inhibitors (HDACi). The mechanism of action …

[引用][C] 探讨组蛋白甲基化修饰在次生代谢产物调控中的作用

刘爽, 袁媛, 黄璐琦, 查良平, 周骏辉, 刘勇 - 生命的化学, 2016